Table 1

Immunotherapies in development for the treatment of Hodgkin lymphoma

TrialAgents investigatedAgent descriptionPrimary outcome for assessment
CheckMate 812 (NCT03138499)Nivolumab+BV vs BV monotherapy in patients with R/R cHL, not eligible for autoSCTICI, ADCPFS
NCTN S1826
Nivolumab+AVD vs BV+AVD (A-AVD) for first-line treatment of stage III or IV cHLICIPFS
MK-3475–204/KEYNOTE-204 (NCT02684292)Pembrolizumab vs BV for R/R cHLICIPFS, OS
NCT02572167BV+nivolumab for R/R cHLICI, ADCRate of AEs, CR rate
  • A-AVD, brentuximab vedotin, doxorubicin, vinblastine, dacarbazine; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; ADC, antibody-drug conjugate; AEs, adverse events; BV, brentuximab vedotin; cHL, classical Hodgkin lymphoma; CR, complete response; ICI, immune checkpoint inhibitor; mAb, monoclonal antibody; OS, overall survival; PFS, progression-free survival; R/R, relapsed or refractory.